Recombinant Human MLKL Protein ，His & SUMO

MLKL (Mixed Lineage Kinase Domain-Like Protein) is a crucial protein involved in the process of necroptosis, a form of programmed cell death. This pathway is distinct from apoptosis and is activated under certain stress conditions, particularly when the tumor necrosis factor (TNF) signaling is disrupted. The study of MLKL has garnered significant interest due to its role in various diseases, including cancer, neurodegenerative disorders, and inflammatory conditions. Researchers have identified that upon activation by receptor-interacting protein kinases (RIPK1 and RIPK3), MLKL undergoes conformational changes, leading to its oligomerization and subsequent translocation to cellular membranes, where it disrupts membrane integrity and induces cell death. Understanding the structure and function of MLKL is essential for elucidating the molecular mechanisms of necroptosis and could reveal new therapeutic targets for treating diseases characterized by dysregulated cell death. Recent advances in recombinant protein technology have allowed for the expression and purification of MLKL, facilitating detailed biophysical and biochemical studies. These studies aim to characterize the oligomeric state of MLKL, its interactions with membrane lipids, and the downstream effects of its activity. Such insights could pave the way for novel strategies in modulating necroptosis, offering potential avenues for intervention in various pathologies where this cell death pathway plays a critical role.